gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Myocyte enhancer factor 2B

The product of this gene is a member of the MADS/MEF2 family of DNA binding proteins. The protein is thought to regulate gene expression, including expression of the smooth muscle myosin heavy chain gene. This region undergoes considerable alternative splicing, with transcripts supporting two non-overlapping loci (geneID:729991 and 100271849) as well as numerous read-through transcripts that span both loci (annotated as geneID:4207). Several isoforms of this protein are expressed from either this locus or from some of the read-through transcripts annotated on geneID:4207. [provided by RefSeq, Mar 2009] (from NCBI)
Top mentioned proteins: MMP-3, CAN, Histone, HAD, bcl-6
Papers on MEF2B
Toward personalized lymphoma immunotherapy: Identification of common driver mutations recognized by patient CD8+ T cells.
Nelson et al., Colombia. In Clin Cancer Res, Jan 2016
T cell responses were directed toward putative driver mutations in CREBBP and MEF2B.
MEF2 transcription factors: developmental regulators and emerging cancer genes.
Marra et al., Vancouver, Canada. In Oncotarget, Nov 2015
In particular, MEF2B, the most divergent and least studied protein of the MEF2 family, has a role unique from its paralogs in non-Hodgkin lymphomas.
Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.
Bernstein et al., Cambridge, United States. In Cancer Discov, Oct 2015
We show that BCL6-locus enhancers are acetylated by the BCL6-activating transcription factor MEF2B, and can undergo genomic duplication, or target the MYC promoter for activation in the context of a "pseudo-double-hit" t(3;8)(q27;q24) rearrangement linking the BCL6 and MYC loci.
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Weigert et al., München, Germany. In Lancet Oncol, Sep 2015
FINDINGS: We established a clinicogenetic risk model (termed m7-FLIPI) that included the mutation status of seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11), the Follicular Lymphoma International Prognostic Index (FLIPI), and Eastern Cooperative Oncology Group (ECOG) performance status.
Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas.
Krenács et al., Szeged, Hungary. In Virchows Arch, Sep 2015
Myocyte enhancer binding factor 2 B (MEF2B) is a member of the evolutionary conserved transcription family MEF2.
BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Quentmeier et al., Hannover, Germany. In Haematologica, Jun 2015
Subclone-specific expression of the aryl-hydrocarbon receptor (AhR) and the resulting activity of the AhR/ARNT complex underlaid differential regulation of 11 genes including MEF2B.
MEF2B-Nox1 signaling is critical for stretch-induced phenotypic modulation of vascular smooth muscle cells.
Pagano et al., Pittsburgh, United States. In Arterioscler Thromb Vasc Biol, Feb 2015
This study was designed to test the hypothesis that pathological CS stimulates NADPH oxidase isoform 1 (Nox1)-derived ROS via MEF2B, leading to VSMC dysfunction via a switch from a contractile to a synthetic phenotype.
The molecular characterization and temporal-spatial expression of myocyte enhancer factor 2 genes in the goat and their association with myofiber traits.
Zhang et al., Chengdu, China. In Gene, Feb 2015
The myocyte enhancer factor-2 (MEF2) gene family in vertebrates includes MEF2A, MEF2B, MEF2C, and MEF2D, which have important functions in the regulation of muscular growth and development.
MEF2 transcription factors regulate distinct gene programs in mammalian skeletal muscle differentiation.
Naya et al., Boston, United States. In J Biol Chem, Feb 2015
Whereas MEF2A is absolutely required for proper myoblast differentiation, MEF2B, -C, and -D were found to be dispensable for this process.
Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Lieberman et al., Philadelphia, United States. In J Virol, 2014
EBNA1 bound to genes of high significance for B-cell growth and function, including MEF2B, IL6R, and EBF1.
MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.
Marra et al., Vancouver, Canada. In Nat Commun, 2014
Myocyte enhancer factor 2B (MEF2B) is a transcription factor with mutation hotspots at K4, Y69 and D83 in diffuse large B-cell lymphoma (DLBCL).
Molecular pathogenesis of follicular lymphoma.
Nishikori et al., Kyoto, Japan. In J Clin Exp Hematop, 2013
With recent advances in the technology for DNA analysis, recurrent gene aberrations such as TNFRSF14, EPHA7, EZH2, CREBBP, EP300, MLL2 and MEF2B have been identified.
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
Dalla-Favera et al., New York City, United States. In Nat Immunol, 2013
MEF2B encodes a transcriptional activator and is mutated in ∼11% of diffuse large B cell lymphomas (DLBCLs) and ∼12% of follicular lymphomas (FLs).
Role of myocyte enhancing factor 2B in epithelial myofibroblast transition of human gingival keratinocytes.
Chamulitrat et al., Heidelberg, Germany. In Exp Biol Med (maywood), 2012
MEF2B has a role in myogenic transformation of the epithelial to a myofibroblast phenotype
[Properties comparing and evolutionary analysis of MEF2 of Homo sapiens based on bioinformatic methods].
Guo, Xi'an, China. In Yi Chuan, 2011
The phylogenetic tree result shows that MEF2B may be original because of its difference of sequences and evolutional relation.
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Marra et al., Vancouver, Canada. In Nature, 2011
32% of diffuse large B-cell lymphoma and 89% of follicular lymphoma cases had somatic mutations in MLL2, and 11.4% and 13.4% of DLBCL and FL cases, respectively, had mutations in MEF2B
Galpha13 regulates MEF2-dependent gene transcription in endothelial cells: role in angiogenesis.
Voyno-Yasenetskaya et al., Chicago, United States. In Angiogenesis, 2008
MEF2 proteins are an important component in Galpha13-mediated angiogenesis.
Cooperation between MEF2 and PPARgamma in human intestinal beta,beta-carotene 15,15'-monooxygenase gene expression.
Rubin et al., Providence, United States. In Bmc Mol Biol, 2005
Study demonstrates that human intestinal cell BCMO1 expression is dependent on the functional cooperation between peroxisome proliferator-activated receptor-gamma and myocyte enhancer factor 2 isoforms.
Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2.
Chen et al., Boulder, United States. In Nature, 2003
Crystal structure of the MADS-box/MEF2S domain of human MEF2B bound to a motif of the transcriptional co-repressor Cabin1 and DNA at 2.2 A resolution
share on facebooktweetadd +1mail to friends